Perrigo Completes $110 Million Sale of Israeli Business

November 26, 2017 | Pharma biotech company Perrigo has completed the sale of its Israeli-based active pharmaceutical ingredients (API) business to New York investment firm SK  Capital for $110 million last week. The deal was first announced in August. In the agreement, Perrigo API, now called Wavelength Pharmaceuticals, will continue to supply existing and commercial APIs to Perrigo under a longterm contract. SK Capital currently has over $1.9 billion assets under management. It usually invests in specialty materials, chemicas, and pharmaceuticals. The companies it invests in tend to generate annual revenues of as much as $6 billion.